These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1967845)

  • 21. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys.
    Madsen MV; Peacock LP; Werge T; Andersen MB; Andreasen JT
    Neuropharmacology; 2011; 60(2-3):418-22. PubMed ID: 21029743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.
    Nadal R
    CNS Drug Rev; 2001; 7(3):265-82. PubMed ID: 11607043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Remoxipride, a selective antagonist of dopamine D2 receptors, in the treatment of delusional psychoses].
    Lewander T; Westerberg SE; Ogren SO; Von Bahr C; Köhler C
    Encephale; 1990; 16(2):153-7. PubMed ID: 1972054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of apomorphine and haloperidol on "spontaneous" stereotyped licking behaviour in the Cebus monkey.
    Korsgaard S; Povlsen UJ; Randrup A
    Psychopharmacology (Berl); 1985; 85(2):240-3. PubMed ID: 3925490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates.
    Casey DE; Bruhwyler J; Delarge J; Géczy J; Liégeois JF
    Psychopharmacology (Berl); 2001 Sep; 157(3):228-35. PubMed ID: 11605077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective dopamine D2 antagonist and prolactin response in acute schizophrenia--results from remoxipride studies. The Canadian Remoxipride Study Group.
    Awad AG; Lapierre YD; Jostell KG
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):769-77. PubMed ID: 2149882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine D-2 antagonists reverse apomorphine-induced decreased water intake in the rat: prediction of antipsychotic drugs with few extrapyramidal side-effects?
    Ljungberg T
    J Neural Transm; 1989; 76(2):79-90. PubMed ID: 2565360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.
    Ogren SO; Rosén L; Fuxe K
    Neuroscience; 1994 Jul; 61(2):269-83. PubMed ID: 7969908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
    Lublin H; Gerlach J; Mørkeberg F
    Psychopharmacology (Berl); 1994 Apr; 114(3):495-504. PubMed ID: 7855208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
    Chouinard G
    J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs.
    Magnusson O; Fowler CJ; Köhler C; Ogren SO
    Neuropharmacology; 1986 Feb; 25(2):187-97. PubMed ID: 2939362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys.
    Casey DE
    Psychopharmacology (Berl); 1992; 107(1):18-22. PubMed ID: 1534177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.
    Hall H; Sällemark M; Jerning E
    Acta Pharmacol Toxicol (Copenh); 1986 Jan; 58(1):61-70. PubMed ID: 2869639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical pharmacology of the atypical neuroleptic remoxipride.
    Köhler C; Hall H; Magnusson O; Lewander T; Gustafsson K
    Acta Psychiatr Scand Suppl; 1990; 358():27-36. PubMed ID: 1978484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of D1 receptor stimulation in normal and MPTP monkeys.
    Bédard PJ; Boucher R
    Neurosci Lett; 1989 Sep; 104(1-2):223-8. PubMed ID: 2573015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
    Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
    Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.
    Migler BM; Warawa EJ; Malick JB
    Psychopharmacology (Berl); 1993; 112(2-3):299-307. PubMed ID: 7871034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers.
    Christoffersen CL; Meltzer LT
    Neuropsychopharmacology; 1998 May; 18(5):399-402. PubMed ID: 9536454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remoxipride, a specific D2 dopamine antagonist: an examination of its self-administration liability and its effects on d-amphetamine self-administration.
    Amit Z; Smith BR
    Pharmacol Biochem Behav; 1992 Jan; 41(1):259-61. PubMed ID: 1347174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.